KDR/FLK-1 Cancer Research Results

KDR/FLK-1, Kinase insert Domain-Containing Receptor/Fetal Liver Kinase-1: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
KDR/FLK-1 (Kinase insert Domain-Containing Receptor/Fetal Liver Kinase-1) is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation.
Scientific Papers found: Click to Expand⟱
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
angioG↓, 0.5 approximately 50 micromol/l
TumCG↓,
VEGF↓, remarkably lowered VEGF expression on tumor cells
KDR/FLK-1↓,
*toxicity↓, known low toxicity of ART

556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓,
IL1↓, IL-1β
TNF-α↓,
TGF-β↓, TGF-β1
NF-kB↓,
MIP2↓,
PGE2↓,
NO↓,
Hif1a↓,
KDR/FLK-1↓,
VEGF↓,
MMP2↓,
TIMP2↑,
ITGB1↑,
NCAM↑,
p‑ATM↑,
p‑ATR↑,
p‑CHK1↑,
p‑Chk2↑,
Wnt/(β-catenin)↓,
PI3K↓,
Akt↓,
ERK↓, ERK1/2
cMyc↓,
mTOR↓,
survivin↓,
cMET↓,
EGFR↓,
cycD1/CCND1↓,
cycE1↓,
CDK4/6↓,
p16↑,
p27↑,
Apoptosis↑,
TumAuto↑,
Ferroptosis↑,
oncosis↑,
TumCCA↑, G0/G1 into M phase, G0/G1 into S phase, G1 and G2/M
ROS↑, ovarian cancer cell line model, artesunate induced oxidative stress, DNA double-strand breaks (DSBs) and downregulation of RAD51 foci
DNAdam↑,
RAD51↓,
HR↓,

3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells
Apoptosis↑, Shikonin suppressed the cellular growth of RPMI8226 and IM9 myeloma cells, via induction of apoptosis in a dose (0–1 μM)- and time (0–24 h)-dependent manner.
TumCCA↑, Treatment with 0.5 μM Shikonin rapidly increased the population of cells in the G0/G1 phase with reduction of cells in the S phase
MMP↓, Shikonin-induced apoptosis was in association with the loss of mitochondrial transmembrane potentials, and activation of caspase-3.
Casp3↑,
P53↑, Expression of p53 and Bax proteins was increased with down-regulation of Mcl-1 protein
BAX↑,
Mcl-1↓,
EGFR↓, Shikonin has reported to be an inhibitor of protein tyrosine kinase such as EGFR, v-Src, and KDR/Flk-1.
Src↑,
KDR/FLK-1↓,
p‑IGF-1↓, Shikonin inhibited phosphorylation of IGF-1 receptor as early as 30 min with inhibition of PI3K/Akt signaling
PI3K↓,
Akt↓,


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 2,   BAX↑, 1,   Casp3↑, 1,   p‑Chk2↑, 1,   Ferroptosis↑, 1,   Mcl-1↓, 1,   oncosis↑, 1,   p27↑, 1,   survivin↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 1,   HR↓, 1,   p16↑, 1,   P53↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   cycE1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   ERK↓, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   mTOR↓, 1,   PI3K↓, 2,   Src↑, 1,   TumCG↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

CDK4/6↓, 1,   ITGB1↑, 1,   MMP2↓, 1,   NCAM↑, 1,   TGF-β↓, 1,   TIMP2↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 2,   Hif1a↓, 1,   KDR/FLK-1↓, 3,   NO↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

IL1↓, 1,   IL6↓, 1,   MIP2↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   IL6↓, 1,  
Total Targets: 55

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: KDR/FLK-1, Kinase insert Domain-Containing Receptor/Fetal Liver Kinase-1
2 Artemisinin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:789  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page